Evolus Market Capitalization from 2010 to 2025
| EOLS Stock | USD 12.24 0.19 1.53% |
Check Evolus financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evolus' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 19.7 M or Selling General Administrative of 207.9 M, as well as many indicators such as Price To Sales Ratio of 4.3, Dividend Yield of 0.0 or PTB Ratio of 130. Evolus financial statements analysis is a perfect complement when working with Evolus Valuation or Volatility modules.
Evolus | Market Capitalization |
Latest Evolus' Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Evolus Inc over the last few years. It is Evolus' Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evolus' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 790.38 M | 10 Years Trend |
|
Market Cap |
| Timeline |
Evolus Market Capitalization Regression Statistics
| Arithmetic Mean | 328,964,928 | |
| Geometric Mean | 290,155,242 | |
| Coefficient Of Variation | 55.75 | |
| Mean Deviation | 140,349,939 | |
| Median | 271,318,062 | |
| Standard Deviation | 183,395,964 | |
| Sample Variance | 33634.1T | |
| Range | 605.5M | |
| R-Value | 0.78 | |
| Mean Square Error | 14005.6T | |
| R-Squared | 0.61 | |
| Significance | 0.0003 | |
| Slope | 30,119,042 | |
| Total Sum of Squares | 504511.2T |
Evolus Market Capitalization History
About Evolus Financial Statements
Evolus shareholders use historical fundamental indicators, such as Market Capitalization, to determine how well the company is positioned to perform in the future. Although Evolus investors may analyze each financial statement separately, they are all interrelated. The changes in Evolus' assets and liabilities, for example, are also reflected in the revenues and expenses on on Evolus' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Evolus operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 174 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Evolus Stock Analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.